Format

Send to

Choose Destination
J Cancer Res Clin Oncol. 2011 Oct;137(10):1409-18. doi: 10.1007/s00432-011-1039-4. Epub 2011 Aug 30.

The CDK inhibitors in cancer research and therapy.

Author information

1
Department of Medicine, Institute of Anatomy, University of Fribourg, Rte. Albert- Gockel 1, 1700, Fribourg, Switzerland. j.cicenas@mapkinases.eu

Abstract

Chemical compounds that interfere with an enzymatic function of kinases are useful for gaining insight into the complicated biochemical processes in mammalian cells. Cyclin-dependent kinases (CDK) play an essential role in the control of the cell cycle and/or proliferation. These kinases as well as their regulators are frequently deregulated in different human tumors. Aberrations in CDK activity have also been observed in viral infections, Alzheimer's, Parkinson's diseases, ischemia and some proliferative disorders. This led to an intensive search for small-molecule CDK inhibitors not only for research purposes, but also for therapeutic applications. Here, we discuss seventeen CDK inhibitors and their use in cancer research or therapy. This review should help researchers to decide which inhibitor is best suited for the specific purpose of their research. For this purpose, the targets, commercial availability and IC(50) values are provided for each inhibitor. The review will also provide an overview of the clinical studies performed with some of these inhibitors.

PMID:
21877198
DOI:
10.1007/s00432-011-1039-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center